Current market-leading therapies in the U.S. COPD market will face challenges from emerging drugs, especially generic versions of Spiriva, Symbicort, and Advair. Surveyed physicians often report that familiarity is a key driver of drug selection within a class, but clinical factors are significant both for physicians and MCOs. Cost-control measures are critical for MCOs, and have a moderate impact on prescribing decisions.

Pharmacoeconomic data are anticipated to be of increasing importance, especially with the launch of additional therapies within the LABA/LAMA class and the new LABA/LAMA/ICS FDC class.


Related Reports

Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast

The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15...

View Details

Chronic Obstructive Pulmonary Disease | Disease Landscape and Forecast | G7 | 2020

The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs) tow...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

View Details